ATA7162000A - Verwendung von n-anisoyl-gamma-aminobuttersäure oder p-anissäure zur herstellung einer pharmazeutischen zusammensetzung - Google Patents

Verwendung von n-anisoyl-gamma-aminobuttersäure oder p-anissäure zur herstellung einer pharmazeutischen zusammensetzung

Info

Publication number
ATA7162000A
ATA7162000A AT0071600A AT7162000A ATA7162000A AT A7162000 A ATA7162000 A AT A7162000A AT 0071600 A AT0071600 A AT 0071600A AT 7162000 A AT7162000 A AT 7162000A AT A7162000 A ATA7162000 A AT A7162000A
Authority
AT
Austria
Prior art keywords
acid
aminobutteric
anisoyl
gamma
producing
Prior art date
Application number
AT0071600A
Other languages
English (en)
Other versions
AT408836B (de
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ATA7162000A publication Critical patent/ATA7162000A/de
Application granted granted Critical
Publication of AT408836B publication Critical patent/AT408836B/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT0071600A 1999-04-27 2000-04-25 Verwendung von n-anisoyl-gamma-aminobuttersäure oder p-anissäure zur herstellung einer pharmazeutischen zusammensetzung AT408836B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99108223 1999-04-27

Publications (2)

Publication Number Publication Date
ATA7162000A true ATA7162000A (de) 2001-08-15
AT408836B AT408836B (de) 2002-03-25

Family

ID=8238054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0071600A AT408836B (de) 1999-04-27 2000-04-25 Verwendung von n-anisoyl-gamma-aminobuttersäure oder p-anissäure zur herstellung einer pharmazeutischen zusammensetzung

Country Status (24)

Country Link
US (1) US20030073744A1 (de)
JP (1) JP2000309529A (de)
KR (1) KR100372906B1 (de)
CN (1) CN1277019A (de)
AR (1) AR023763A1 (de)
AT (1) AT408836B (de)
AU (1) AU3011300A (de)
BE (1) BE1013314A3 (de)
BR (1) BR0002381A (de)
CA (1) CA2307022A1 (de)
DE (1) DE10020237A1 (de)
DK (1) DK200000687A (de)
ES (1) ES2176078A1 (de)
FI (1) FI20000977A (de)
FR (1) FR2792833B1 (de)
GB (1) GB2351662A (de)
GR (1) GR1003591B (de)
IE (1) IE20000308A1 (de)
IT (1) IT1318490B1 (de)
NL (1) NL1015043C2 (de)
PT (1) PT102456B (de)
SE (1) SE0001499L (de)
TR (1) TR200001133A2 (de)
ZA (1) ZA200002041B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5273731B2 (ja) * 2009-08-11 2013-08-28 独立行政法人産業技術総合研究所 生体リズムの制御剤
EP3878287A4 (de) * 2018-11-13 2021-11-24 Peng, Xianfeng Verwendung eines acylierten aminosäurederivats bei der herstellung von tierfutterzusatz

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU21107A3 (es) * 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
JPH1081626A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk チロシナーゼ活性阻害剤
JPH1081607A (ja) * 1996-09-06 1998-03-31 Kamiyama:Kk 抗菌剤

Also Published As

Publication number Publication date
NL1015043C2 (nl) 2001-03-30
CA2307022A1 (en) 2000-10-27
KR100372906B1 (ko) 2003-02-17
FR2792833A1 (fr) 2000-11-03
JP2000309529A (ja) 2000-11-07
CN1277019A (zh) 2000-12-20
GR20000100145A (el) 2000-12-29
FI20000977A (fi) 2000-10-27
IE20000308A1 (en) 2000-11-29
SE0001499D0 (sv) 2000-04-26
US20030073744A1 (en) 2003-04-17
DK200000687A (da) 2000-10-28
ITMI20000914A0 (it) 2000-04-21
GB2351662A (en) 2001-01-10
SE0001499L (sv) 2000-10-28
ZA200002041B (en) 2000-10-27
FR2792833B1 (fr) 2002-09-06
FI20000977A0 (fi) 2000-04-26
AU3011300A (en) 2000-11-02
BR0002381A (pt) 2000-11-07
PT102456B (pt) 2003-04-30
AT408836B (de) 2002-03-25
NL1015043A1 (nl) 2000-10-30
BE1013314A3 (fr) 2001-11-06
DE10020237A1 (de) 2001-02-08
AR023763A1 (es) 2002-09-04
PT102456A (pt) 2000-11-30
ITMI20000914A1 (it) 2001-10-21
TR200001133A2 (tr) 2000-11-21
IT1318490B1 (it) 2003-08-25
ES2176078A1 (es) 2002-11-16
GB0010049D0 (en) 2000-06-14
KR20010029658A (ko) 2001-04-06
GR1003591B (el) 2001-05-22

Similar Documents

Publication Publication Date Title
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE60017336D1 (de) Zusammensetzung zur Herstellung von Harzen
DE19983486T1 (de) Verfahren zur Herstellung von Citalopram
DE69906389T2 (de) Verfahren zur herstellung von citalopram
DE60015734D1 (de) Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation
DE69922660D1 (de) Ein verfahren zur herstellung von terephthalsäure oder dimethylterephthalat
ATE401309T1 (de) Verwendung von 2-fuoro-3-ketoestern zur herstellung von 3-fuoro-6,7,8,9-tetrahydro-4h- pyrimidoä1,2-aüpyrimidin-4-onen
DE60100858D1 (de) Prozess zur herstellung der kristallinen form i von cabergolin
DE69903698T2 (de) Verfahren zur Herstellung von Acrylsäure
DE60127446D1 (de) Verfahren zur herstellung von 5-cyanovaleriansäure oder adipinsäure
DE60008830D1 (de) Verfahren zur Herstellung von keramischen Zusammensetzungen
DE69935509D1 (de) Verfahren zur herstellung von durchscheinenden zahnersätzen
ATE314850T1 (de) Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
DE69822711D1 (de) Verfarhen zur Herstellung von Dialkylnaphthalinen
DE60033877D1 (de) Verfahren zur Herstellung von Dimethylsulfoxid
DE60043261D1 (de) Verfahren zur herstellung von phenylessigsäure derivaten
DE69927048D1 (de) Ibandroinsäure zur förderung der osseointegration der endoprothesen
DE69901243D1 (de) Artikulator zur herstellung von zahnärztlichen prothesen
DE69813053D1 (de) Verfahren zur Herstellung von optisch aktiven Azetidin-2-Carbonsäurederivaten
DE69815179D1 (de) Verfahren zur Herstellung von D-Glucoronsäurelacton
DE60033207D1 (de) Werkzeug zur herstellung von nockenwellen durch einwalzen
ATA7162000A (de) Verwendung von n-anisoyl-gamma-aminobuttersäure oder p-anissäure zur herstellung einer pharmazeutischen zusammensetzung
DE69935355D1 (de) Verfahren zur Herstellung von Citalopram
DE60029847D1 (de) Verfahren zur Herstellung von erythro 3-Amino-2-hydroxybuttersäurederivaten
DE69812438T2 (de) Zusammensetzung zur herstellung von brennstoff-briketts

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee